Relationship between remnant cholesterol and risk of kidney stones in U.S. Adults: a 2007–2016 NHANES analysis

References

• Mao W, Zhang H, Xu Z, et al. Relationship between urine specific gravity and the prevalence rate of kidney stone. Transl Androl Urol. 2021;10(1):1–14. doi: 10.21037/tau-20-929.
   PubMed Web of Science ®Google Scholar
• Mao W, Wang K, Xu B, et al. ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol Cancer. 2021;20(1):142. doi: 10.1186/s12943-021-01443-2.
   PubMed Web of Science ®Google Scholar
• Abufaraj M, Xu T, Cao C, et al. Prevalence and trends in kidney stone among adults in the USA: analyses of national health and nutrition examination survey 2007-2018 data. Eur Urol Focus. 2021;7(6):1468–1475. doi: 10.1016/j.euf.2020.08.011.
   PubMedGoogle Scholar
• Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. Nat Rev Nephrol. 2020;16(12):736–746. doi: 10.1038/s41581-020-0320-7.
   PubMed Web of Science ®Google Scholar
• Shavit L, Ferraro PM, Johri N, et al. Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol Dial Transplant. 2015;30(4):607–613. doi: 10.1093/ndt/gfu350.
   PubMed Web of Science ®Google Scholar
• Türk C, Petřík A, Sarica K, et al. EAU guidelines on interventional treatment for urolithiasis. Eur Urol. 2016;69(3):475–482. doi: 10.1016/j.eururo.2015.07.041.
   PubMed Web of Science ®Google Scholar
• Varbo A, Nordestgaard BG. Remnant cholesterol and triglyceride-Rich lipoproteins in atherosclerosis progression and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2016;36(11):2133–2135.
   PubMed Web of Science ®Google Scholar
• Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol. 2019;85(4):550–559. doi: 10.1002/ana.25432.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141(3):358–367. doi: 10.1016/j.pharmthera.2013.11.008.
   PubMed Web of Science ®Google Scholar
• Yan P, Xu Y, Miao Y, et al. Association of remnant cholesterol with chronic kidney disease in Middle-aged and elderly chinese: a population-based study. Acta Diabetol. 2021;58(12):1615–1625. doi: 10.1007/s00592-021-01765-z.
   PubMed Web of Science ®Google Scholar
• Chang C-W, Ke H-L, Lee J-I, et al. Metabolic syndrome increases the risk of kidney stone disease: a Cross-Sectional and longitudinal cohort study. J Pers Med. 2021;11(11):1154. doi: 10.3390/jpm11111154.
   PubMed Web of Science ®Google Scholar
• Qiu F, Xu Y, Ji X, et al. Incidence and correlation of metabolic syndrome and kidney stones in a healthy screening population. Transl Androl Urol. 2021;10(9):3646–3655. doi: 10.21037/tau-21-689.
   PubMed Web of Science ®Google Scholar
• Zou Y, Kuang M, Zhong Y, et al. Remnant cholesterol can identify individuals at higher risk of metabolic syndrome in the general population. Sci Rep. 2023;13(1):5957. doi: 10.1038/s41598-023-33276-y.
   PubMed Web of Science ®Google Scholar
• Quispe R, Martin SS, Michos ED, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021;42(42):4324–4332. doi: 10.1093/eurheartj/ehab432.
   PubMed Web of Science ®Google Scholar
• Cao Y-X, Zhang H-W, Jin J-L, et al. The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovasc Diabetol. 2020;19(1):104. doi: 10.1186/s12933-020-01076-7.
   PubMed Web of Science ®Google Scholar
• Yu D, Wang Z, Zhang X, et al. Remnant cholesterol and cardiovascular mortality in patients with type 2 diabetes and incident diabetic nephropathy. J Clin Endocrinol Metab. 2021;106(12):3546–3554. doi: 10.1210/clinem/dgab533.
   PubMed Web of Science ®Google Scholar
• Jepsen A-MK, Langsted A, Varbo A, et al. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clin Chem. 2016;62(4):593–604. doi: 10.1373/clinchem.2015.253757.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi: 10.1093/eurheartj/ehw272.
   PubMed Web of Science ®Google Scholar
• Quispe R, Elshazly MB, Zhao D, et al. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. Eur J Prev Cardiol. 2020;27(15):1597–1605. doi: 10.1177/2047487319862401.
   PubMed Web of Science ®Google Scholar
• Quispe R, Michos ED, Martin SS, et al. High-sensitivity C-Reactive protein discordance with atherogenic lipid measures and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. J Am Heart Assoc. 2020;9(3):e013600. doi: 10.1161/JAHA.119.013600.
   PubMed Web of Science ®Google Scholar
• Lawler PR, Akinkuolie AO, Ridker PM, et al. Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women. Clin Chem. 2017;63(4):870–879. doi: 10.1373/clinchem.2016.264515.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282. doi: 10.1016/j.cjca.2016.07.510.
   PubMed Web of Science ®Google Scholar
• Mao W, Zhang L, Sun S, et al. Physical activity reduces the effect of high body mass index on kidney stones in diabetes participants from the 2007-2018 NHANES cycles: a cross-sectional study. Front Public Health. 2022;10:936552. doi: 10.3389/fpubh.2022.936552.
   PubMedGoogle Scholar
• Carr SS, Hooper AJ, Sullivan DR, et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148–154. doi: 10.1016/j.pathol.2018.11.006.
   PubMed Web of Science ®Google Scholar
• Huang H, Guo Y, Liu Z, et al. Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease. J Clin Endocrinol Metab. 2022;107(8):e3295–e303. doi: 10.1210/clinem/dgac283.
   PubMed Web of Science ®Google Scholar
• Elshazly MB, Mani P, Nissen S, et al. Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol. 2020;27(10):1091–1100. doi: 10.1177/2047487319887578.
   PubMed Web of Science ®Google Scholar
• Bonfiglio C, Leone CM, Silveira LVA, et al. Remnant cholesterol as a risk factor for cardiovascular, cancer or other causes mortality: a competing risks analysis. Nutr Metab Cardiovasc Dis. 2020;30(11):2093–2102. doi: 10.1016/j.numecd.2020.07.002.
   PubMed Web of Science ®Google Scholar
• Sakhaee K, Maalouf NM, Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97(6):1847–1860. doi: 10.1210/jc.2011-3492.
   PubMed Web of Science ®Google Scholar
• Dawson CH, Tomson CRV. Kidney stone disease: pathophysiology, investigation and medical treatment. Clin Med (Lond). 2012;12(5):467–471.
   PubMed Web of Science ®Google Scholar
• Curhan GC, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993;328(12):833–838.
   PubMed Web of Science ®Google Scholar
• Hu H, Zhang J, Lu Y, et al. Association between circulating vitamin D level and urolithiasis: a systematic review and Meta-Analysis. Nutrients. 2017;9(3):301. doi: 10.3390/nu9030301.
   PubMed Web of Science ®Google Scholar
• Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669–683. doi: 10.1056/NEJMoa055218.
   PubMed Web of Science ®Google Scholar
• Lappe J, Watson P, Travers-Gustafson D, et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA. 2017;317(12):1234–1243. doi: 10.1001/jama.2017.2115.
   PubMed Web of Science ®Google Scholar
• Khan SR, Glenton PA. Increased urinary excretion of lipids by patients with kidney stones. Br J Urol. 1996;77(4):506–511.
   PubMedGoogle Scholar
• Schmiedl A, Schwille PO, Bonucci E, et al. Nephrocalcinosis and hyperlipidemia in rats fed a cholesterol- and fat-rich diet: association with hyperoxaluria, altered kidney and bone minerals, and renal tissue phospholipid-calcium interaction. Urol Res. 2000;28(6):404–415.
   PubMedGoogle Scholar
• Thomas G, Sehgal AR, Kashyap SR, et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364–2373. doi: 10.2215/CJN.02180311.
   PubMed Web of Science ®Google Scholar
• Jeong IG, Kang T, Bang JK, et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis. 2011;58(3):383–388. doi: 10.1053/j.ajkd.2011.03.021.
   PubMed Web of Science ®Google Scholar
• Kang HW, Seo SP, Kim WT, et al. Hypertriglyceridemia is associated with increased risk for stone recurrence in patients with urolithiasis. Urology. 2014;84(4):766–771. doi: 10.1016/j.urology.2014.06.013.
   PubMed Web of Science ®Google Scholar
• Inci M, Demirtas A, Sarli B, et al. Association between body mass index, lipid profiles, and types of urinary stones. Ren Fail. 2012;34(9):1140–1143. doi: 10.3109/0886022X.2012.713298.
   PubMed Web of Science ®Google Scholar
• Chang IH, Lee YT, Lee DM, et al. Metabolic syndrome, urine pH, and time-dependent risk of nephrolithiasis in korean men without hypertension and diabetes. Urology. 2011;78(4):753–758. doi: 10.1016/j.urology.2011.03.007.
   PubMed Web of Science ®Google Scholar
• Kang HW, Lee SK, Kim WT, et al. Hypertriglyceridemia and low high-density lipoprotein cholesterolemia are associated with increased hazard for urolithiasis. J Endourol. 2014;28(8):1001–1005. doi: 10.1089/end.2014.0135.
   PubMed Web of Science ®Google Scholar
• Ding Q, Ouyang J, Fan B, et al. Association between dyslipidemia and nephrolithiasis risk in a chinese population. Urol Int. 2019;103(2):156–165. doi: 10.1159/000496208.
   PubMed Web of Science ®Google Scholar
• de Water R, Leenen PJ, Noordermeer C, et al. Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages. Am J Kidney Dis. 2001;38(2):331–338.
   PubMed Web of Science ®Google Scholar
• Khan SR. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol. 2013;189(3):803–811. doi: 10.1016/j.juro.2012.05.078.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjærg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298–1309. doi: 10.1161/CIRCULATIONAHA.113.003008.
   PubMed Web of Science ®Google Scholar
• Hong L-F, Yan X-N, Lu Z-H, et al. Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease. Lipids Health Dis. 2017;16(1):7. doi: 10.1186/s12944-017-0410-0.
   PubMedGoogle Scholar